Abstracts tagged "tocilizumab and efficacy"

Abstract Number: 1181 • 2019 ACR/ARP Annual Meeting
Tocilizumab in Aortitis: A Multicenter Study of 79 Patients
Mónica Calderón-Goercke¹, Javier Loricera ², DIANA PRIETO- PENA ³, Vicente Aldasoro Caceres ⁴, Santos Castañeda ⁵, Ignacio Villa ⁶, Alicia Humbría ⁷, Clara Moriano ⁸, Susana Romero-Yuste ⁹, Javier Narváez ¹⁰, Catalina Gómez-Arango ¹¹, Eva Perez Pampín ¹², Rafael Melero ¹³, Marcelino Revenga ¹⁴, Noelia Álvarez-Rivas ¹⁵, Francisca Sivera ¹⁶, María Álvarez del buergo ¹⁷, Luisa Marena-Rojas ¹⁸, Eva Galindez-Agirregoikoa ¹⁹, Beatriz Arca ²⁰, Roser Solans-Laqué ²¹, Carlos Vazquez ²², Pau Lluch ²³, Eva salgado-Pérez ²⁴, Cristina Luna-Gómez ²⁵, F. Javier Toyos-Sáenz De Miera ²⁶, Nagore Fernández-Llanio ²⁷, Antonio García ²⁸, Carmen Larena ²⁹, Lara Sanchez-Bilbao ¹, Iñigo Gonzalez-Mazon ³, Natalia Palmou-Fontana ³, Vanesa Calvo-Río ¹, Carmen González-Vela ¹, Alfonso Corrales ³⁰, María Varela-García ⁴, Elena Aurrecoechea ⁶, Raquel Dos Santos ³¹, Sabela Fernández ²⁰, Jose Luis Hernández ¹, Miguel Angel González-Gay ³² and Ricardo Blanco ³³, ¹Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, ²Rheumatology Department. Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, ³Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ⁴Complejo Hospitalario de Navarra, Navarra, Navarra, Spain, ⁵Rheumatology Department, Hospital Universitario de la Princesa, IIS-Princesa, Madrid, Spain, Madrid, Spain, ⁶Hospital de Sierrallana, Torrelavega, Cantabria, Spain, ⁷Hospital de La Princesa, Madrid, Madrid, Spain, ⁸Complejo Asistencial Universitario de León, León, Castilla y Leon, Spain, ⁹Complejo Hospitalario Universitario Pontevedra, Pontevedra, Galicia, Spain, ¹⁰Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, Barcelona, Catalonia, Spain, ¹¹Hospital Alto Deba, Mondragon, Pais Vasco, Spain, ¹²Division of Rheumatology, Instituto de Investigación Sanitaria-Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, Santiago de Compostela, Spain, ¹³Complexo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, ¹⁴Hospital Ramón y Cajal, Madrid, Madrid, Spain, ¹⁵Hospital Universitario Lucus Augusti, Lugo, Galicia, Spain, ¹⁶Hospital General Universitario de Elda, Elda, Spain, ¹⁷Hospital Río Carrión, Palencia, Castilla y Leon, Spain, ¹⁸Hospital La Mancha Centro, Alcázar de San Juan, Castilla-La Mancha, Spain, ¹⁹Hospital de Basurto, Bilbao, Pais Vasco, Spain, ²⁰Hospital Universitario San Agustín, Avilés, Asturias, Spain, ²¹Department of Internal Medicine, Hospital Vall d'Hebron, Barcelona, Spain., Barcelona, Catalonia, Spain, ²²Hospital Miguel Servet, Zaragoza, Aragon, Spain, ²³Hospital Mateu Orfila, Menorca, Islas Baleares, Spain, ²⁴Complejo Hospitalario Universitario de Ourense, Ourense, Galicia, Spain, ²⁵Hospital Universitario Nuestra Señora de la Candelaria, Tenerife, Canarias, Spain, ²⁶Hospital Universitario Virgen Macarena, Sevilla, Andalucia, Spain, ²⁷Hospital Arnau de Vilanova, Lérida, Catalonia, Spain, ²⁸Hospital Virgen de las Nieves, Granada, Andalucia, Spain, ²⁹Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, ³⁰Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, ³¹Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Galicia, Spain, ³²Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³³Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain
Background/Purpose: Aortitis can be idiopathic or associated with other conditions. It is frequently refractory to conventional immunosuppressive therapy. Tocilizumab (TCZ), an anti-IL-6 receptor antibody seems…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].